Genix Pharmaceuticals Corporation Share Price

Equities

GENX

CA37232A1093

Food Processing

Market Closed - Toronto S.E. 07:00:00 01/05/2024 pm IST 5-day change 1st Jan Change
0.04 CAD -20.00% Intraday chart for Genix Pharmaceuticals Corporation 0.00% +100.00%

Financials

Sales 2022 - Sales 2023 12.35K 9K 751K Capitalization 2.37M 1.73M 144M
Net income 2022 -1M -729K -60.8M Net income 2023 -4M -2.92M -243M EV / Sales 2022 -
Net Debt 2022 173K 126K 10.53M Net Debt 2023 500K 365K 30.39M EV / Sales 2023 232 x
P/E ratio 2022
-3.58 x
P/E ratio 2023
-0.54 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 56.65%
More Fundamentals * Assessed data
Dynamic Chart
Genix Pharmaceuticals Corporation Reports Earnings Results for the First Quarter Ended January 31, 2024 CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2023 CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023 CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023 CI
Genix Pharmaceuticals Corporation Announces Board Changes CI
Genix Pharmaceuticals Corporation Auditor Raises 'Going Concern' Doubt CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2022 CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022 CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2022 CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the First Quarter Ended January 31, 2022 CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2021 CI
Genix Pharmaceuticals Corporation Auditor Raises 'Going Concern' Doubt CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter Ended July 31, 2021 CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter Ended April 30, 2021 CI
Genix Pharmaceuticals : Starts Trading on OTCQB Venture Market Exchange MT
More news
1 day-20.00%
Current month-42.86%
1 month-38.46%
Current year+100.00%
More quotes
1 month
0.04
Extreme 0.04
0.08
Current year
0.03
Extreme 0.03
0.08
1 year
0.02
Extreme 0.015
0.08
3 years
0.02
Extreme 0.015
0.25
5 years
0.01
Extreme 0.01
0.30
10 years
0.00
Extreme 0
0.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 11/19/11
Chairman - 19/21/19
Director of Finance/CFO - 14/20/14
Members of the board TitleAgeSince
Director of Finance/CFO - 14/20/14
Director/Board Member 74 11/19/11
Chairman - 19/21/19
More insiders
Date Price Change Volume
01/24/01 0.04 -20.00% 1,000
30/24/30 0.05 -16.67% 4,100

Delayed Quote Toronto S.E., May 01, 2024 at 07:00 pm IST

More quotes
Genix Pharmaceuticals Corporation is a nutraceutical and generic ophthalmic drugs company. The Company is focused on the research, development, manufacturing, licensing, and sales of healthcare products. Its products include evidence-based, proprietary over the counter (OTC) nutraceuticals, and other single-molecule generic drugs. The Company is engaged in marketing and selling other nutraceuticals and some pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels and spirulina powder. Its products include Ketorolac 0.5% Eye Drops, Bimatoprost 0.01% Eye Drops, Timolol 0.5% Eye Drops, Loteprednol 0.5% Eye Drops, Diclofenac 0.1% Eye Drops, Brimonidine 0.2% Eye Drops. The Company sells its ophthalmic products through traditional pharmacy and drugstore retail outlets and as well as direct to consumers and e-commerce platforms.
More about the company